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Abstract
Lower hemoglobin

is

associated

with

cognitive

impairment

and

Alzheimer's

disease (AD). Since brain iron homeostasis is perturbed in AD, we investigated
whether this is peripherally reflected in the hematological and related blood
chemistry values from the Australian Imaging Biomarker and Lifestyle (AIBL) study (a
community-based, cross-sectional cohort comprising 768 healthy controls (HC), 133
participants with mild cognitive impairment (MCI) and 211 participants with AD). We
found that individuals with AD had significantly lower hemoglobin, mean cell hemoglobin
concentrations, packed

cell

volume

and

higher

erythrocyte sedimentation

rates (adjusted for age, gender, APOE-ε4 and site). In AD, plasma iron, transferrin,
transferrin saturation, and red cell folate levels exhibited a significant distortion of their
customary relationship to hemoglobin levels. There was a strong association
between anemia and AD (adjusted OR=2.43 (CI[1.31, 4.54])). Moreover, AD emerged
as a strong risk factor for anemia on step-down regression, even when controlling for all
other available explanations for anemia (adjusted OR=3.41 95%CI[1.68, 6.92]). These
data indicated that AD is complicated by anemia, which may itself contribute to cognitive
decline.
Keywords:
Anemia, Alzheimer's disease, Mild Cognitive Impairment, hemoglobin, iron, folate,
hematology.
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Introduction
115.4 million cases of Alzheimer's disease (AD) world-wide are expected by
2050,1 an impetus to understand this incurable dementia. AD and unexplained anemia
are the most common diagnoses in nursing homes, both with a prevalence of ≈45% in
this setting.2,3 Several reports have associated lower hemoglobin and anemia on a
cross-sectional basis with poorer cognition,4-6 and recently low hemoglobin has featured
on a biomarker panel with high diagnostic accuracy for AD.7 Two prospective studies of
elderly populations have reported that anemia and lower levels of hemoglobin were
associated with a ≈2-fold increased hazard for developing AD over ≈3 years.2,8 These
studies speculated that low hemoglobin could be a systemic manifestation of AD.
Hemoglobin is the most abundant iron-protein in the body but is also synthesized
in cortical neurons, where iron metabolism is severely perturbed in AD. Neocortical
neurons in AD have decreased hemoglobin levels9, and elevated iron levels that
promote oxidative damage.10,11 Genetic evidence supporting a role for abnormal ironassociated metabolism in AD includes a risk polymorphism of hemoglobin12 and a
synergistic risk effect for variants of iron-regulatory genes transferrin with HFE.13, 14 APP
plays an important role in cellular iron export.11,15 An increase in IRP1 binding to the
APP Iron Responsive Element in erythrocytes in AD compared to age-matched controls
indicates that the central abnormality of hemoglobin and iron regulation in AD might be
reflected in the blood.16.
In the present study, we investigated the association of AD with anemia and the
causes of anemia in AD. We analyzed iron-related blood biochemistry, hemoglobin and
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other blood chemistry values that may impact on anemia in the large Australian
Imaging, Biomarker and Lifestyle (AIBL) cohort of healthy controls (HC), mild cognitive
impairment (MCI) and AD patients.
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Material and Methods
Study design and participants
Recruitment and characteristics of this cohort were previously described17. AIBL
is a two-site (Melbourne, Perth), prospective study of aging, integrating data from
neuroimaging, biomarkers, clinical and neuropsychological measurements and lifestyle
information. Volunteers are in cohorts of: a.) AD by NINCDS-ADRDA criteria, b.) Mild
Cognitive Impairment (MCI, associated with an increased risk for developing AD), and
c.) cognitively healthy individuals (healthy controls, HC) (Supplementary Material,
sections Participant Recruitment and Cohort Size for details).
AIBL was approved by the institutional ethics committees of Austin Health, St.
Vincent’s Health, Hollywood Private Hospital, and Edith Cowan University. Written
informed consent was obtained from all study participants.

Procedures
Baseline blood samples were taken from overnight fasting participants, and
fractionated or forwarded to clinical pathology laboratories for analysis as described1
(Supplementary Material, section Biochemistry for details). Anemia diagnosis is detailed
in Supplementary Material, section Anemia Diagnosis. All participants were given the
Food Frequency Questionnaire developed by the Cancer Council of Victoria
(Supplementary Material, Iron and Folate Dietary Intake for details).
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Statistical analysis
Analysis was performed with R version 2.15.2 (packages, Supplementary
Material, sections Statistical Analysis). Pearson’s χ2 assessed differences in the
distributions of the missing data, genders and APOE ε4 incidence. Analysis of variance
(ANOVA) assessed difference in age across the clinical classifications, followed by
Tukey honest significant differences to test the pairwise comparisons.
Clinical pathology data were checked for normality by inspection of histograms
and quartile-quartile plots. For those that deviated from normality, Box-Cox18 analysis
was performed. The transformed data were then checked for normality.
Analysis of covariance (ANCOVA) was used with age, gender and site as
confounding variables (ApoE-ε4 genotype was initially included, but was identified as a
non-significant main effect and was not included in the final models.) to test the
difference between the clinical classifications and continuous data. False discovery
rate19 (FDR) was used to correct for multiple testing. For the analysis of iron, dietary iron
was also included as a confounding variable. The analysis of both serum and red cell
folate were also adjusted for dietary folate. The results presented are the adjusted
means and standard errors (SE). The pairwise analysis was corrected for multiple
testing by controlling for FDR. Adjusted p-values are presented (Supplementary
Material, sections Statistical Analysis for details).
Fisher Exact tests were used to analyze the number of subjects above or below a
given reference range between two groups. The p-values reported are FDR-adjusted for
multiple testing.
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Logistic regression was used to assess the odds ratio (OR) of having AD given
the anemia state (true/false), and vice versa, i.e. OR of being anemic based on the
cognitive classification (HC/AD) (Supplementary Material, sections Statistical Analysis
for details). To compare the log odds estimates between two logistic regression models,
model with all subjects included and one with the subject with anemia of inflammation
removed, bootstrapping with 1000 replicates was performed.
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Results
Data from the initial baseline cohort17 were analyzed. The HC group was
significantly younger than the MCI and AD groups (p<0.001), and the MCI group was
significantly younger than the AD group (p<0.01). There were significantly more females
in the combined cohort, particularly in the HC and AD groups. The AD group had
significantly more APOEε4 allele carriers compared to the HC (p<0.001) and the MCI
(p=0.033) groups, and the MCI group had significantly more ε4 carriers than the HC
group (p<0.001) (Supplementary Table 1). There were small numbers of missing
biochemical data, but not biased to any clinical group (Supplementary Figure 1).
We initially examined 23 clinicopathology test results deemed relevant to red cell
synthesis and iron metabolism. None of the adjusted (gender, site, age) mean values
lay outside of the clinical reference ranges, but ANCOVA revealed significant
differences across the three clinical groups for hemoglobin, MCH, MCHC, PCV, red cell
folate (decreased in AD), ESR and haptoglobin (increased in AD), with a trend to
decreased plasma iron in AD (Table 1). While transferrin was not significantly different
across the clinical groups (p=0.905), transferrin levels declined more steeply with age in
AD (p=0.045) (Supplementary Figure 2).
Pair-wise comparison of these eight values of interest across the clinical groups
(figure 1A-H) revealed that iron, hemoglobin, MCH, MCHC, and PCV were significantly
decreased in AD compared to HC, and ESR was significantly elevated in AD compared
to HC. MCI values lay between the HC and AD values for iron, hemoglobin, MCH, and
MCHC. Only for MCHC were the differences significant between HC and MCI as well as
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AD and MCI (HC>MCI>AD). ESR and PCV were significantly different only between
MCI and AD (MCI≈HC). In the ANCOVA for plasma iron, dietary iron intake was not a
significant confounder and was removed from the final model. While haptoglobin
showed a significant difference across the clinical groups, the individual pairwise
comparisons showed only a trend towards increase in AD (figure 1H).
Since there was a significant decrease in hemoglobin levels and red cell
hemoglobin content in the AD cohort, we analyzed the association between anemia
(WHO criteria20: males hemoglobin<130 g/L, females hemoglobin<120 g/L) and AD by
logistic regression, finding a strong unadjusted association (OR=5.94 95%CI[3.13,
9.94], p<0.001). Adjusted for known major AD risk factors, age, gender and APOE-ε4
status, the OR for being diagnosed as AD if anemic in this cohort was 2.43
(95%CI[1.30, 4.54], p=0.005) (table 2A), consistent with previous reports.4,8,21.
Conversely, higher MCHC was protective for AD (OR= 0.62, 95%CI[0.48-0.80],
p<0.001, adjusted for age, gender and APOE-ε4 status).
We then interrogated the reciprocal OR, for being anemic if diagnosed as AD,
and controlled for confounders for the risk of anemia. As expected, increasing RDW,
urea, ESR and erythropoietin, decreasing WCC, iron and ceruloplasmin all showed an
association with anemia within the combined HC/AD cohort (table 2B). Surprisingly,
increasing ferritin was associated with anemia, as was increasing red cell folate (but
only in AD cases). AD emerged as a strong risk factor for anemia, even when controlling
for all other available explanations for anemia (adjusted OR=3.41, 95%CI[1.68, 6.92],
p<0.001) (table 2B). Neither iron nor folate dietary intake were confounders. Similarly,
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while zinc and copper deficiency are uncommon causes of anemia, plasma zinc and
copper were not significant terms in the OR model (not shown). Non-steroidal antiinflammatory drugs (NSAIDs) may contribute to anemia by promoting GI bleeding,
although we found no evidence of blood loss to account for the increased risk of anemia
in the AD cohort. Nevertheless, χ2 tests indicated no bias in the number of subjects on
NSAIDs compared to those not on NSAIDs between the anemic and non-anemic groups
within in AD and HC cohorts (p = 0.552, p = 0.200, respectively, Supplementary Table
S2). Acetylcholinesterase inhibitors can also potentially cause GI bleeding (by MalloryWeiss syndrome). χ2 testing showed no bias in the usage of acetylcholinesterase
inhibitors between anemic AD and non-anemic AD subjects (p = 0.204, Supplementary
Table S3).
Taken together, these data indicate that AD is associated with a proclivity to
anemia that could not be explained by known risk factors. To explore possible
explanations for the proclivity towards anemia identified in the AD cohort, we analyzed
the proportional prevalence of abnormal clinical pathology results (outside the reference
range). These were indeed more prevalent in the AD group compared to the HC and
MCI groups (13 out of 29 tests, expanded to include white cell sub-population counts,
Supplementary Table 4), with no abnormality being more prevalent in the HC cohort.
Abnormal results in MCI patients lay in prevalence between HC and AD abnormalities.
The older age of the AD cohort could account for the increased prevalence of
abnormal tests, so we created age-matched MCI and HC groups (Supplementary Table
1B) and repeated this analysis. The prevalence of abnormalities for the AD cohort
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remained significantly greater than HC for low levels of hemoglobin (18.54 vs 7.47%,
AD:HC), PCV (20.49% vs 12.03%), transferrin saturation (9.27% vs 3.78%), serum iron
(5.85% vs 1.26%), and serum folate (8.33 vs 1.67%), with elevations of ESR (46.70% vs
33.33%), haptoglobin (42.51% vs 30.25%), ferritin (17.56% vs 7.98%) and TSH (9.80%
vs 3.77%) (table 3). Differences in dietary intake could not account for the increased
prevalence of serum folate and iron abnormalities observed.
Confining this analysis to age-matched anemia cases only, no clinical pathology
abnormality was

significantly more prevalent between HC and AD cohorts

(Supplementary Table 5). ANCOVA of the hematology and biochemical data, controlling
for age and gender, revealed small differences between anemic AD and HC subjects
(Supplementary Table 6) for MCHC, lymphocyte count, bilirubin, and transferrin
saturation (males only), but did not reveal a clearly different signature between the AD
and HC anemic subjects.
As reticulocyte counts were not available, we used plasma erythropoietin levels
as an indication of drive for red cell production. As expected, elevated erythropoietin
levels were observed in the anemic cohort (p=0.003, Supplementary Figure 3), and
associated with anemia risk (OR 1.45 CI[1.10, 1.92], table 2B). ANCOVA, controlling for
age, gender, site and clinical classification, revealed no significant difference in
erythropoietin across the neurological categories (p=0.103, table 1).
When anemia cases were categorized on the basis of clinical pathology
abnormalities, anemia of chronic inflammation (AI) was the only anemia category
significantly more prevalent in the AD group (28.9% of types of anemia) compared to
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the age-matched HC group (16.7%, p<0.001; Supplementary Figure 4 and
Supplementary Table 7).
AI is characterized by an elevation of interleukin-6 (IL-6).22 However, IL-6 was not
elevated in the AD cohort (Table 1). ANCOVA (adjusted for age, gender and site)
revealed an elevation of IL-6 in subjects with anemia (p = 0.005), but no interaction
between IL-6, anemia and neurological category (p = 0.826). To determine the extent
that the increased risk for anemia in the AD group is accounted for by AI, we compared
two logistic models, model 1 (m1) using all subjects and model 2 (m2) where the AI
subjects were removed. There was no change in the AD OR for anemia (OR difference
[m1 – m2] -0.181 (95%CI[-1.79, 1.67], p = 0.807) when the AI subjects were removed.
The risk for anemia in the AD cohort using m2 was still strong (adjusted OR=3.59,
95%CI[1.68, 6.95], p = 0.002). Therefore, AI does not explain the increased prevalence
of anemia in AD.
These findings suggest that AD patients may have a defect in hemoglobin
synthesis of unknown etiology. To characterize this we examined the relationships
between levels of hemoglobin and its substrates: plasma iron, transferrin, transferrin
saturation, haptoglobin and red cell folate. Using multiple regression analysis
(controlling for age, gender and clinical classification), the relationship between
hemoglobin (as a product) and each factor (as a precursor) showed an inverted-U
shaped quadratic association (p<0.001) for each clinical cohort. The associations of
hemoglobin as a product of either plasma iron, transferrin level, transferrin saturation or
red cell folate were all significantly altered in the AD group (p<0.001, figure 2) in that
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hemoglobin levels dropped precipitously as the substrate levels approached the
margins of the normal range. The haptoglobin-hemoglobin relationship was not affected
by clinical classification (p=0.5472). For the relationship between hemoglobin and red
cell folate there was a steeper decline in hemoglobin levels in AD patients who had red
cell folate levels above 1000 nmol/L (figure 2D), recapitulating the surprising
observation that elevated red cell folate increased the risk for anemia in AD patients
only (table 2B). These relationships were not significantly perturbed in the MCI cohort.
The puzzling association of higher levels of red cell folate with anemia (table 2B,
figure 2D), together with significantly lower red cell folate levels (-13%, table 1, figure
1G) in the AD cohort, could reflect anomalous folate metabolism in AD. Serum folate
levels were not significantly changed in AD (table 1). So we analyzed the age-matched
cohort for participants who had the mismatched combination of abnormally low serum
folate with normal (or elevated) red cell folate. This combination of results was indeed
uncommon in the HC group (0.5%) but was significantly more frequent in the MCI
(3.8%, p=0.005) and AD (6.6%, p<0.001) groups (Supplementary Table 8). Indeed, in
AD it was more common than abnormally low red cell folate (Supplementary Table 8). In
addition, the mean ratio of red cell to serum folate, reflecting the exchange of folate
between intracellular and extracellular blood compartments, was significantly elevated in
anemic AD subjects (figure 1I), with no change in anemic HC and MCI subjects, Since
nutritional intake of folate did not explain the increased prevalence of anemia in AD,
these data implicate altered exchange of folate between serum and red cells as
potentially contributory to the increased risk for anemia in AD.
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Discussion
Anemia is an established risk factor for cognitive loss, causally attributed to low
oxygenation of obligatorily aerobic cortical tissue.2,4,5,21. In the AIBL cohort, people with
anemia were 2.40-fold more likely to have AD (adjusting for age and APOE-ε4), and
anemia emerged as a stronger potential risk factor for AD than aging 5 years (table 2A).
These findings are consistent with a prospective study that reported anemia as a risk
factor for AD, accelerating cognitive decline to a degree similar to aging 12 years.8
Therefore, identifying and treating anemia in older age could be imperative. However,
our findings indicate that management of anemia in AD may not be straightforward. AI
was more common in the AD cohort, but neither AI nor other known causes could
explain the increased risk for anemia or lower hemoglobin levels in AD.
Idiopathic anemia becomes prevalent in advanced age, and indeed, in the AIBL
cohort reversible causes of anemia were rare and idiopathic anemia was the most
common cause (Supplementary Figure 4 and Supplementary Table 7). Is it possible that
an impairment of hemoglobin production is a systemic manifestation of AD, and that
since sub-clinical AD pathology also becomes prevalent above the age of 60, could
idiopathic anemia itself be etiologically related to AD? Abnormalities of red cells have
been reported in studies of smaller AD cohorts.23-26 We found that on average, AD red
cells are smaller, have less concentrated hemoglobin, sediment faster and have lower
folate levels than HC red cells (figure 1). For these results, MCI red cells have values
between AD and HC.
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As with idiopathic anemia, we could not ascertain a clear etiological explanation
for the lowering of hemoglobin in AD, but we detected changes in systemic iron, folate
metabolism, thyroid, and inflammation that could adversely impact hemoglobin
production. Importantly, the relationships between hemoglobin and its iron-related
precursors (serum iron, transferrin and transferrin saturation) were perturbed in AD
(figure 2A-C). Unlike HC and MCI, hemoglobin levels in AD declined significantly unless
serum iron, transferrin and transferrin saturation were in the middle of the normal range.
Therefore, iron-related hemoglobin production may be brittle in AD. The significantly
greater prevalence of abnormally high serum ferritin in AD (17.65%) compared to agematched HC subjects (7.98%, table 3) together with significantly lower plasma iron
levels (figure 1A) and increased prevalences of abnormally low serum iron and
transferrin saturation (table 3) in AD, argue that iron accumulates in tissue stores and is
not adequately mobilized in AD. This is consistent with iron accumulation in the
neocortex in AD.11
Folate deficiency is a risk factor for both dementia and anemia, and while we
observed folate changes in AD, they could not be accounted for by nutritional deficiency
or medication. Serum folate levels were not significantly changed In the AD group
compared to the age-matched HC group, but subnormal levels were significantly more
prevalent (8.33% vs 1.67%, table 3). This might be consistent with a nutritional problem,
but red cell folate is a better reflection of long-term deficiency27 and while red cell folate
levels were decreased in the AD group (figure 1G),28 subnormal levels were uncommon
and not more prevalent in AD than in HC (table 3). Alternatively, a systemic defect in
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folate metabolism that could contribute to the increased prevalence of anemia in AD
was evidenced by the brittle relationship between hemoglobin levels and red cell folate
in AD (figure 2D), as well as the puzzling observation that increasing red cell folate
strongly increases the risk for anemia in AD but not HC subjects (table 2B). Abnormal
folate metabolism has been implicated in AD pathogenesis. A genome wide association
study

identified

a

significant

association

between

polymorphisms

of

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like protein and the
risk for late-onset AD.29 A proteomic study found that methylenetetrahydrofolate
dehydrogenase 1 levels are 32-fold elevated in erythrocytes in AD compared to
controls.26 Folate is susceptible to oxidation, notably by elevated cytosolic iron.30
Hypothyroidism might also contribute to the increased incidence of anemia in AD
since abnormally elevated TSH was more common (9.80%) than age-matched HC
(3.77%, table 3). However, adjusted mean TSH levels were not lower in the AD cohort,
indicating that the contribution of hypothyroidism to anemia in AD is limited.
Inflammation may play a role in lowering hemoglobin in AD, since we observed
elevated ESR, suppressed serum iron, elevated ferritin, and suppressed transferrin in
the AD cohort (tables 1 and 3), and AI was the only diagnostic category for anemia that
was significantly more prevalent (+12.2%) in the AD cohort compared to HC
(Supplementary Figure 4 and Supplementary Table 7). However, logistic regression
analysis excluding AI cases still determined that AD was a risk factor for anemia, and
inflammation does not explain the differential tendency to lower hemoglobin levels in AD
that we have observed. However, hepcidin and CRP levels in AD may be valuable in
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appraising the tendency to anemia.
Therefore, the etiology of the 3.41-fold increase in anemia in AD involves
perturbances of multiple systems for hemoglobin synthesis. Hemolysis could be
excluded since haptoglobin was elevated in AD (table 1), as others have also
reported31. While the mechanism of this idiopathic hemoglobin defect in AD remains to
be determined, we note that Aβ binds hemoglobin,32 and hemoglobin accumulates in
the hallmark cortical amyloid plaque and congophilic angiopathy of AD.33 Aβ is enriched
in red cell membranes in AD compared to healthy controls,34,35 and oxidizes red cell
hemoglobin,36 potentially contributing to anemia in AD.
With the caveat that this is a cross-sectional study and the subjects were
recruited via advertising, so not a true random sample of the Australian population, our
findings identify AD as a novel risk factor for anemia. Since low hemoglobin itself
impairs cognition, and is a risk factor for AD, the hemoglobin lesion of AD may not be an
epiphenomenon. The interrelationship between AD and hemoglobin warrants closer
investigation as a potential target for intervention.

Supplementary information is available at Molecular Psychiatry's website
(http://www.nature.com/mp)
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Measurement (units)
[reference range]

HC

MCI

AD

p-value

Iron (µmol/L)
[M:7-35, F:7-30]

21.93 (0.22)

21.28 (0.52)

20.76 (0.43)

0.079

Transferrin (µmol/L)
[M:23-43, F:23-46]

32.96 (0.18)

33.09 (0.45)

33.16 (0.4)

0.890a

Transferrin Saturation (%)
[M:14 - 53, F:14-48]

27.02 (0.35)

26.37 (0.83)

25.66 (0.69)

0.289

Ceruloplasmin (g/L)
[0.17-0.55]

0.312 (0.002)

0.316 (0.005)

0.305 (0.004)

0.122

Ferritin (µg/L)
[M:15-200, F:30-370b]

120.25 (3.46)

115.08 (8.01)

114.40 (6.75)

0.828

Hemoglobin (g/L)
[M:130-180, F:120-160]

140.96 (0.4)

139.93 (0.95)

137.62 (0.82)

0.012

RCC (x1012/L)
[M:4.5-5.7, F:3.8-5.1]

4.51 (0.02)

4.51 (0.04)

4.44 (0.03)

0.117

MCV (fL)
[80-96]

91.35 (0.15)

91.09 (0.36)

90.99 (0.31)

0.642

MCH (pg)
[27-33]

31.20 (0.06)

31.00 (0.14)

30.85 (0.12)

0.044

MCHC (g/L) [320-360]

341.54 (0.21)

340.21 (0.51)

338.78 (0.43)

< 0.001

RDW (%) [11-15]

13.36 (0.03)

13.29 (0.07)

13.37 (0.06)

0.650

PCV (L/L)
[M:0.4-0.5, F:0.35-0.45]

0.412 (0.001)

0.411 (0.003)

0.402 (0.002)

0.014

ESR (mm/hr)
[1-35]

11.07 (0.29)

10.88 (0.7)

13.12 (0.7)

0.029

Serum folate (nmol/L)c
[7-40]

946.39 (29.03)

847.46 (74.89)

887.74 (65.47)

0.468

Red cell folate (nmol/L) c
[230-1600]

970.56 (14.67)

901.38 (38.37)

862.96 (31.89)

0.014

B12 (pmol/L)
[120-680]

293.78 (4.77)

284.91 (10.96)

291.10 (9.62)

0.817

Bilirubin (µmol/L)
[<19]

11.85 (0.15)

11.98 (0.37)

11.37 (0.28)

0.324

TSH (mU/L)
[0.1-4.0]

1.60 (0.04)

1.67 (0.1)

1.67 (0.08)

0.817

Haptoglobin (g/L)
[0.3 – 2.0]

1.48 (0.03)

1.57 (0.09)

1.63 (0.08)

0.031

Erythropoietin (pg/mL) d
[32.92 – 222.21

71.25 (2.81)

90.03 (9.33)

73.53 (5.31)

0.103
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WCC (x109/L)
[4-11]

1.73 (0.01)

1.75 (0.02)

1.78 (0.02)

0.122

Urea (mmol/L)
[2.5 – 8.3]

1.78 (0.01)

1.77 (0.02)

1.79 (0.02)

0.122e

IL 6 (pg/mL)
[<5]

1.68 (0.04)

1.85 (0.11)

1.74 (0.08)

0.367

Table 1: Hematological and associated clinical chemistry mean values in the
clinical categories. Age, gender and site-adjusted means (standard error) and
adjusted p-values (ANCOVA, controlling for false discovery rate [FDR]) are shown for
the three clinical classifications.
a

Interaction between clinical classification and age (p=0.046).

b

Female ferritin reference range: pre-menopause: 20-220µg/L, post-menopause: 30-

370 µg/L.
c

d

Adjusted for dietary folate intake.
Erythropoietin analysis performed on the non-imputed data. Reference range as

defined by ARUP Laboratories.
e

Interaction between clinical classification and age (p=0.040).
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Factor

A
Non–anemic, APOE-ε4 non-carrier,
healthy control

Odds ratio (95% CI)

P value

for Alzheimer's disease
Reference

Age (per 5 yrs)

1.95 (1.71—2.21)

<0.001

APOE-ε4 carrier

5.52 (3.71—8.22)

< 0.001

Female

0.94 (0.63–1.39)

0.741

Anemia

2.43 (1.31—4.54)

0.005

0.62 (0.48-0.80)

<0.001

MCHC (per 8 g/L)

B
Non-anemic, healthy control

for anemia
Reference

WCC (per 1.8 x109/L)

0.47 (0.30-0.74)

0.001

RDW (per 1%)

1.75 (1.37-2.24)

< 0.001

Ceruloplasmin (per 0.08 g/L)

0.53 (0.32-0.87)

0.012

Ferritin (per 124 µg/L)

1.48 (1.19-1.84)

0.001

Iron (per 7.29 µmol/L)

0.17 (0.09-0.32)

< 0.001

Urea (per 2 mmol/L)

1.75 (1.32-2.32)

< 0.001

ESR (per 12 mm/hr)

1.77 (1.37-2.29)

< 0.001

Erythropoietin (per 74 ng/L)

1.44 (1.10-1.89)

0.008

Red cell folate [HC] (per 518 nmol/L
increase)

0.97 (0.60-1.57)

0.914

Red cell folate [AD] (per 518 nmol/L
increase)

2.39 (1.36-4.22)

0.002

Alzheimer's disease

3.41 (1.68-6.92)

<0.001

Table 2. Logistic regression analysis of risk factors. The odds ratios for the
continuous variables were calculated for the interquartile ranges (except for age) of the
27

whole cohort. A. The odds ratios of having an AD diagnosis in the cohort, with reference
to non–anemic, APOE-ε4 non-carrier, cognitively healthy controls. Anemia and MCHC
emerged as significant adjusted risks for AD from the backwards step analysis, together
with known risks, age and APOE-ε4 carrier status. Model fit statistics: Nagelkerke
R2=0.391, c-statistic=84.4%, Somers' Dxy=0.688 and Brier score=0.111. B. The odds
ratios of being anemic, with reference to non–anemic, cognitively healthy controls.
Alzheimer’s disease emerged as a risk factor, even when adjusted for all known risk
factors for anemia from the backwards step analysis. There was a significant interaction
between clinical classification and red cell folate (p=0.002), so odd ratios are presented
for both healthy controls and Alzheimer's disease. Model fit statistics: Nagelkerke
R2=0.535, c-statistic=93.2%, Somers' Dxy=0.865 and Brier score=0.039.
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Below Reference Range

Fe
[238, 108, 205]
Transferrin
[238, 108, 205]
Transf’n Sat’n
[238, 108, 205]
Ceruloplasmin
[238, 108, 205]
Ferritin
[238, 108, 205]
Hemoglobin
[241, 109, 205]
RCC
[241, 109, 205]
MCV
[241, 109, 205]
MCH
[241, 109, 205]
MCHC
[241, 109, 205]
RDW
[241, 109, 205]
PCV
[241, 109, 205]
ESR
[240, 107, 197]
WCC
[241, 109, 205]
Neutrophils
[241, 109, 205]
Lymphocytes
[241, 109, 205]
Monocytes
[241, 109, 205]
Eosinophils
[241, 109, 205]
Basophils
[241, 109, 205]

Above Reference Range

Total

HC

MCI

AD

pvalue

Adj
pvalue

Pairwise
HC v AD
p-value

Total

HC

MCI

AD

pvalue

Adj
pvalue

0.009

2.00%

2.10%

0.93%

2.44%

0.735

0.948

1.27%

1.68%

1.85%

0.49%

0.425

0.750

3.09%

1.26%

1.85%

5.85%

0.016

0.093

2.36%

1.26%

3.70%

2.93%

0.299

0.630

5.26%

3.78%

0.93%

9.27%

0.003

0.029

7.80%

5.88%

11.11%

8.29%

0.225

0.607

0.91%

1.67%

0.00%

0.49%

0.284

0.630

0.73%

1.26%

0.93%

0.00%

0.257

0.623

2.72%

2.94%

1.85%

2.93%

0.888

1.000

11.98%

7.98%

10.19%

17.56%

0.008

0.058

0.004

11.35%

7.47%

6.42%

18.54%

0.000

0.012

3.42%

2.07%

9.17%

1.95%

0.004

0.029

1.000

21.80%

21.16%

16.51%

25.37%

0.193

0.589

4.50%

3.32%

5.50%

5.37%

0.460

0.750

0.90%

0.41%

0.00%

1.95%

0.220

0.607

7.21%

6.64%

5.50%

8.78%

0.563

0.821

1.26%

0.41%

0.00%

2.93%

0.036

0.187

18.20%

21.16%

15.60%

16.10%

0.304

0.630

0.36%

0.00%

0.00%

0.98%

0.174

0.562

0.00%

0.00%

0.00%

0.00%

1.000

1.000

0.00%

0.00%

0.00%

0.00%

1.000

1.000

6.85%

5.81%

5.50%

8.78%

0.414

0.750

14.23%

12.03%

7.34%

20.49%

0.003

0.029

2.70%

2.49%

5.50%

1.46%

0.130

0.503

1.10%

1.67%

0.00%

1.02%

0.503

0.774

33.82%

33.33%

11.21%

46.70%

0.000

0.000

5.59%

5.39%

9.17%

3.90%

0.158

0.539

1.44%

1.66%

1.83%

0.98%

0.725

0.948

3.60%

4.15%

4.59%

2.44%

0.507

0.774

1.44%

1.66%

2.75%

0.49%

0.230

0.607

25.41%

23.24%

29.36%

25.85%

0.466

0.750

0.54%

0.00%

1.83%

0.49%

0.050

0.242

0.18%

0.41%

0.00%

0.00%

1.000

1.000

2.16%

2.90%

1.83%

1.46%

0.601

0.832

0.00%

0.00%

0.00%

0.00%

1.000

1.000

2.70%

1.24%

5.50%

2.93%

0.075

0.335

0.00%

0.00%

0.00%

0.00%

1.000

1.000

0.90%

1.24%

0.00%

0.98%

0.728

0.948

0.020

0.001

0.052

0.019

Pairwise
HC v AD
p-value

0.006

0.460
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Urea
[240, 108, 205]
Creatinine
[240, 108, 205]
Serum folate
[240, 108, 204]
Red cell folate
[241, 109, 205]
Vitamin B12
[240, 108, 205]
Bilirubin
[239, 108, 205]
TSH
[239, 108, 204]
Haptoglobin
[238, 106, 207]
IL-6
[170, 82, 144]
Erythropoietin
[110, 48, 101]

0.18%

0.00%

0.00%

0.49%

0.566

0.821

16.46%

14.58%

12.04%

20.98%

0.082

0.341

0.00%

0.00%

0.00%

0.00%

1.000

1.000

15.01%

15.00%

13.89%

15.61%

0.927

1.000

4.89%

1.67%

5.56%

8.33%

0.003

0.029

2.54%

2.50%

3.70%

1.96%

0.603

0.832

3.42%

2.90%

3.67%

3.90%

0.826

1.000

5.77%

6.22%

5.50%

5.37%

0.971

1.000

3.44%

2.08%

3.70%

4.88%

0.258

0.623

6.51%

5.00%

7.41%

7.80%

0.432

0.750

0.00%

0.00%

0.00%

0.00%

1.000

1.000

11.41%

10.88%

16.67%

9.27%

0.147

0.534

2.36%

2.09%

1.85%

2.94%

0.817

1.000

5.81%

3.77%

2.78%

9.80%

0.011

0.072

0.012

2.36%

2.52%

3.77%

1.45%

0.346

0.683

33.39%

30.25%

22.64%

42.51%

0.001

0.017

0.008

0.00%

0.00%

0.00%

0.00%

1.000

1.000

10.35%

7.65%

12.20%

12.50%

0.280

0.630

11.20%

10.91%

6.25%

13.86%

0.139

0.750

10.42%

7.27%

12.50%

12.87%

0.353

0.683

0.001

Table 3: Frequency of abnormal clinicopathology results in age-matched clinical cohorts. Frequency of results
above or below the normal reference ranges, within each clinical diagnosis (healthy control, HC, mild cognitive
impairment, MCI, age-matched to Alzheimer's disease, AD). P-values are from Fisher’s exact test for independence,
testing across HC vs AD, and after FDR (Adj p-value). The pairwise comparison was only performed for where there was
a significant difference across all three diagnoses. Bold reflects values that were significantly different on pairwise
comparison; italic reflects near-significant pairwise comparison.
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Figure legends
Figure 1. Changes in hematological and associated clinicopathology adjustedvalues in Alzheimer’s disease. Shown are pair-wise comparisons of clinicopathology
values that are significantly different (on ANCOVA, Table 1) or showing a trend (iron)
across the cohorts. A: iron, B: hemoglobin, C: mean cell hematocrit, D: mean cell
hemoglobin concentration, E: erythrocyte sediment rate, F: packed cell volume, G: red
cell folate, previously reported28, H: haptoglobin, I: the ratio of red cell to serum folate
(rfol/sfol). Shown are the adjusted means (±SE) and p-values from ANCOVA adjusted
for site, age and gender. HC, healthy controls; MCI, mild cognitive impairment, AD,
Alzheimer's disease.

Figure 2. The relationship of blood hemoglobin to precursor levels is perturbed
in AD. Lines of best fit from linear regression models for hemoglobin as a product of A:
plasma iron, B: plasma transferrin (quadratic relationship), C: transferrin saturation, D:
red cell folate. Each shows a quadratic relationship. For all plots, age is fixed at the
population mean (72.2 years). The grey shaded regions are the 95% confidence
intervals. Solid lines- healthy controls, dotted lines- mild cognitive impairment, dashed
lines- Alzheimer's disease. The red vertical lines indicate the min and max of the
reference ranges.
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Figure 2
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